ICS 2012 Scientific Podium Poster Session S7 - LUTS Etiology and Treatment

LUTS Etiology and Treatment

Scientific Podium Poster Session S7

	Wednesday 17th October 2012
	13:30 - 15:30

Session Schedule

14:10

#59 BDNF: a Potential Biomarker of Overactive Bladder

Antunes-Lopes T¹, Pinto R¹, Barros S², Diniz P¹, Martins-Silva C¹, Duarte-Cruz C², Cruz F¹
1. Department of Urology, Hospital de São João, Porto, 2. Experimental Biology Department, Faculty of Medicine, University of Porto

14:15

#60 Brain derived neurotrophic factor (BDNF) is not a valuable biomarker for diagnosing detrusor overactivity.

Bhide A A¹, Gopalan V¹, Cartwright R¹, Digesu G A¹, Puccini F¹, Fernando R¹, Khullar V¹
1. Imperial College London

14:20

#61 ELEVATION OF SERUM HEPATIC GROWTH FACTOR AND NERVE GROWTH FACTOR IN PATIENTS WITH OVERACTIVE BLADDER IMPLIES NERVE FIBERS INCREASING IN URINARY BLADDER

Liu H¹, Kuo H²
1. Department of Urology, Buddhist Tzu Chi General Hospital and Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan, 2. Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan

14:25

#62 URINARY LACTOFERRIN AS A PROMISING, NEW, IMPROVED SURROGATE MARKER FOR URINARY TRACT INFECTION.

Gill K¹, Brenton T², Kupelian A¹, Horsley H³, Sathiananthamoorthy S¹, Collins L⁴, Malone-Lee J¹
1. University College London (UCL), UK, 2. Brighton University Medical School, UK, 3. Royal Veterinary College, UK, 4. University of Southamptom, UK

14:30

#63 Does detrusor overactivity make a difference in women with OAB symptoms?

Jimenez Cidre M A¹, López-Fando L¹, Esteban Fuertes M², Prieto Chaparro L³, Castro Diaz D⁴, Franco de Castro A⁵, Arlandis Guzman S⁶, Salinas Casado J⁷, Gutierrez Ruiz C⁸, Ifu G⁹
1. Department of Urology. Hospital Ramón y Cajal, Madrid, 2. Department of Urology. Hospital de Parapléjicos, Toledo, 3. Department of Urology. Hospital de Elche, Alicante, 4. Department of Urology. Hospital Universitario de Canarias, Tenerife, 5. Department of Urology. Hospital Clinic i Provincial, Barcelona, 6. Department of Urology. Hospital La Fe, Valencia, 7. Department of Urology. Hospital Clinico San Carlos, Madrid, 8. Department of Urology. Fundación Puigvert, Barcelona, 9. Group of Investigation in Functional Urology and Urodynamics

14:35

#64 Etiology and management of acute urinary retention in female patients.

Faruqui N¹, Nadeem M¹, Yasin T¹
1. Aga Khan University

14:40

#65 Efficacy of tamsulosin OCAS 0.4 mg in female with lower urinary tract symptoms: A randomized, double-blind, placebo controlled trial

Helmy H¹
1. Tanta University, Faculty of Medicine, Tanta, Egypt

14:45

#66 The effect of desmopressin combined with anticholinergic on daytime frequency in female patients with overactive bladder

Kim H¹, Lee S H²
1. Dep. of Urology, Kangdong Sacred Heart Hospital,Hallym University, Seoul, Korea, 2. Department of Urology, Chuncheon Sacred Heart Hospital, Hallym University

14:50

#67 The therapeutic effects of orally solifenacin combined with pelvic floor muscle exercises in treatment of female overactive bladder

Jin Y¹, Song E¹, Lv L¹, Li D¹
1. The Harbin 211 Hospital

14:55

#68 The Potent and Selective Beta3-adrenoceptor Agonist Mirabegron Improves Patient-reported Outcomes in Overactive Bladder–Results from Two Phase III Studies

Nitti V¹, Herschorn S², Auerbach S³, Khullar V⁴, Amarenco G⁵, Blauwet M B⁶, Boerrigter P⁷, Hakimi Z⁸, Siddiqui E⁹, Martin N¹⁰
1. NYU Langone Medical Center, Department of Urology, New York, NY, USA, 2. University of Toronto, Division of Urology, Toronto, Canada, 3. Hoag Memorial Presbyterian Hospital, Newport Beach, CA, USA, 4. St Mary’s Hospital, Imperial College, Urogynaecology Department, London, UK, 5. Department of Neurologic Rehabilitation, Urodynamic and Neurophysiology Laboratory, Hôpital Rothschild, Assistance Publique-Hôpitaux de Paris, Paris, France, 6. Astellas Pharma Global Development, Inc., Biostatistics, Deerfield, IL, USA, 7. Astellas Pharma Global Development EU, Leiderdorp, The Netherlands, 8. Astellas Pharma Europe, Leiderdorp, The Netherlands, 9. Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 10. Astellas Scientific and Medical Affairs, Inc. Deerfield, IL, USA

15:00

#69 Functional brain activity and white matter structure are impaired in elderly urge-incontinent subjects compared to normal control.

Tadic S¹, Griffiths D¹, Murrin A¹, Schaefer W¹, Clarkson B¹, Resnick N¹
1. University of Pittsburgh, Department of Medicine, Division of Geriatrics

15:05

#70 The somatic and autonomic innervation of the clitoris; preliminary evidence of sexual dysfunction after minimal invasive slings

Bekker M¹, Hogewoning K¹, Wallner C², Elzevier H¹, deRuiter M³
1. Dept of Urology, Leiden University Medical Center, 2. Dept of Anatomy, Amsterdam Medical Center, 3. Dept of Anatomy, Leiden University Medical Center

15:10

#71 Detection of urinary brain derived neurotrophic factor in patients with benign prostatic hyperplasia after surgical treatment and its correlation with the change of overactive bladder symptom

Xu K¹, Hu H¹, Wang D¹, Wang X¹
1. Department of Urology, Peking University People’s Hospital, Peking University Health Science Center

15:15

#72 Thoracic epidurally administrated bupivacaine affects urethral sphincter tonus in women after open renal surgery

Burkhard F C¹, Metzger T¹, Mordasini L¹, Wuethrich P Y²
1. University Hospital Bern, Department of Urology, Bern, Switzerland, 2. University Hospital Bern, Department of Anesthesiology and Pain Treatment, Bern, Switzerland

15:20

#73 INCREASED RISK OF LARGE POSTVOID RESIDUAL URINE AND LOWER LONG-TERM SUCCESS RATE IN FRAIL PATIENTS 70 YEARS AND OLDER AFTER INTRAVESICAL ONABOTULINUMTOXIN A INJECTION FOR REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY

Liao C¹, Lin V C², Kuo H³
1. Department of Urology, Cardinal Tien Hospital and Fu-Jen University, New Taipei City, Taiwan, 2. Department of Urology, E-Da Hospital, Kaohsiung, Taiwan, 3. Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan

15:25

#74 Modified “Remeex” re-adjustable sling procedure: 2 years follow up – outcomes and safety profiles.

Kaplan E¹
1. Center for Advanced Gynecologic Surgery